Hepatocellular carcinoma (HCC)
Conditions
Interventions
Before RFA, Sorafenib 800mg /day x 7 days po
Sponsors
Yokohama City University Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)HCC patients admitted at this hospital and Child-Pugh Score<=9 2)Performance status:0-2 3)HCC diagnoed by image diagnosis or histology 4)patients with <=3 lesions of small and <=3 cm diameter 5)patients at the age of>=20 and <=80 6)patients who understand this study and sign an informed consent form at the time of enrollment.
Exclusion criteria
Exclusion criteria: 1)T-Bil >=3.0mg/dl,PT <=50% 2)patients during pregnacy, lactation period, or who have a plan to be pregnant 3)patients with massive fluid 4)patient the doctor judged as a non-indication 5)patients with tumor thrombus in the main trunk of portal vein or bile duct 6)severe portal hypertention with treatment-resistant gastric or esophageal varices 7)treatment-resistant ascites 8)bleeding tendency(Plt <=50000/mm3) 9)patients with their prognosis <3 months 10)patient the doctor judged as a non-indication from the medical or mental status
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| coagulation effect | — |
Secondary
| Measure | Time frame |
|---|---|
| (1)bebore,1 week after,4 weeks after,change of tumor marker (2)blood flow changes before and after Sorafenib (3)changes of liver function (4)histological changes before and after Sorafenib | — |
Countries
Japan
Contacts
Public ContactHiroyuki Fukuda
Yokohama City University Medical Center Gastroenterlogical Center
Outcome results
None listed